{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T10:15:23Z","timestamp":1776507323592,"version":"3.51.2"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce both systolic blood pressure (SBP) and diastolic blood pressure (DBP). The glucose-lowering effect of SGLT2i depends on baseline estimated glomerular filtration rate (eGFR), but whether the same is true for the blood-pressure-lowering effect is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We performed a systematic literature review in PubMed (Study 1) and analyzed data from a clinical study (Study 2) to investigate if the blood-pressure-lowering effect of SGLT2i depends on baseline eGFR. In the literature review, we performed a weighted regression analysis with mean change in SBP and DBP as dependent variables and mean eGFR as an independent variable. Furthermore, we analyzed data from a cohort of 48 patients with either type 2 diabetes mellitus with and without chronic kidney disease (CKD) or non-diabetic CKD with varying degrees of kidney function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>In total, 2,069 articles were identified, of which 27 articles met the inclusion criteria. Analysis revealed a mean weighted reduction in SBP \u22124.7 mmHg compared to baseline and \u22123.5 mmHg compared to placebo. The weighted regression analysis showed no correlation between change in SBP and baseline eGFR. Data analysis of 48 patients revealed an SBP reduction of 5.5 mmHg, and the simple linear regression revealed no correlation between the decrease in blood pressure and baseline eGFR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The blood-pressure-lowering effect of SGLT2i does not depend on baseline eGFR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajh\/hpaf130","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T07:49:06Z","timestamp":1751701746000},"page":"122-133","source":"Crossref","is-referenced-by-count":3,"title":["The Effect of SGLT2 Inhibitors on Blood Pressure in Relation to Baseline Kidney Function: A Systematic Literature Review and Data Analysis"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3166-2525","authenticated-orcid":false,"given":"Charlotte Agergaard","family":"M\u00f8ller","sequence":"first","affiliation":[{"name":"University Clinic in Nephrology and Hypertension, G\u00f8dstrup Hospital , Herning ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5410-1088","authenticated-orcid":false,"given":"Steffen Flindt","family":"Nielsen","sequence":"additional","affiliation":[{"name":"University Clinic in Nephrology and Hypertension, G\u00f8dstrup Hospital , Herning ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-5814","authenticated-orcid":false,"given":"Frank Holden","family":"Mose","sequence":"additional","affiliation":[{"name":"University Clinic in Nephrology and Hypertension, G\u00f8dstrup Hospital , Herning ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University , Aarhus ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"2026011413231390600_CIT0001","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","article-title":"Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026011413231390600_CIT0002","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026011413231390600_CIT0003","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026011413231390600_CIT0004","first-page":"2301","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Singh","year":"2023","journal-title":"N Engl J Med"},{"key":"2026011413231390600_CIT0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ahj.2024.02.006","article-title":"Dapagliflozin and blood pressure in patients with chronic kidney disease and albuminuria","volume":"270","author":"Heerspink","year":"2024","journal-title":"Am Heart J"},{"key":"2026011413231390600_CIT0006","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026011413231390600_CIT0007","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"2026011413231390600_CIT0008","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026011413231390600_CIT0009","year":"2025"},{"key":"2026011413231390600_CIT0010","doi-asserted-by":"crossref","first-page":"e56067","DOI":"10.2196\/56067","article-title":"Effects of empagliflozin in type 2 diabetes with and without chronic kidney disease and nondiabetic chronic kidney disease: protocol for 3 crossover randomized controlled trials (SiRENA Project)","volume":"13","author":"Nielsen","year":"2024","journal-title":"JMIR Res Protoc"},{"key":"2026011413231390600_CIT0011","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/dom.14729","article-title":"Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: results from DAPASALT and DIAMOND","volume":"24","author":"Sen","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026011413231390600_CIT0012","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2026011413231390600_CIT0013","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/1479164118782872","article-title":"Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: a randomized open-label prospective trial","volume":"15","author":"Takashima","year":"2018","journal-title":"Diab Vasc Dis Res"},{"key":"2026011413231390600_CIT0014","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/dom.15033","article-title":"Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: a randomized cross-over clinical study","volume":"25","author":"van der Aart-van der Beek","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026011413231390600_CIT0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-019-0912-3","article-title":"Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)","volume":"18","author":"Kinguchi","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2026011413231390600_CIT0016","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/1753-0407.12484","article-title":"Efficacy and safety of dapagliflozin in Asian patients: a pooled analysis","volume":"9","author":"Yang","year":"2017","journal-title":"J Diabetes"},{"key":"2026011413231390600_CIT0017","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2337\/dc20-2604","article-title":"natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial","volume":"44","author":"Scholtes","year":"2021","journal-title":"Diabetes Care"},{"key":"2026011413231390600_CIT0018","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin: a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2026011413231390600_CIT0019","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2026011413231390600_CIT0020","doi-asserted-by":"crossref","first-page":"e016173","DOI":"10.1161\/JAHA.119.016173","article-title":"Acute and chronic effects of SGLT2 Inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized, placebo-controlled trial","volume":"9","author":"Zanchi","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026011413231390600_CIT0021","doi-asserted-by":"crossref","first-page":"e002686","DOI":"10.1136\/rmdopen-2022-002686","article-title":"Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial","volume":"8","author":"Wang","year":"2022","journal-title":"RMD Open"},{"key":"2026011413231390600_CIT0022","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2026011413231390600_CIT0023","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE Study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026011413231390600_CIT0024","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/dom.12936","article-title":"The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients","volume":"19","author":"Petrykiv","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2026011413231390600_CIT0025","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026011413231390600_CIT0026","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2026011413231390600_CIT0027","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026011413231390600_CIT0028","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2026011413231390600_CIT0029","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/dom.14864","article-title":"Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: a secondary analysis of a randomized crossover trial","volume":"25","author":"Scholtes","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026011413231390600_CIT0030","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.12684","article-title":"Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin","volume":"18","author":"Rodbard","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2026011413231390600_CIT0031","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2026011413231390600_CIT0032","doi-asserted-by":"crossref","first-page":"F412","DOI":"10.1152\/ajprenal.00445.2017","article-title":"Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study","volume":"314","author":"Rajasekeran","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026011413231390600_CIT0033","first-page":"63","article-title":"The efficacy and safety of canagliflozin in the treatment of patients with early diabetic nephropathy","volume":"73","author":"Zhang","year":"2022","journal-title":"J Physiol Pharmacol"},{"key":"2026011413231390600_CIT0034","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.dsx.2021.01.011","article-title":"Real world study of short term efficacy, safety, and tolerability of canagliflozin 100\u00a0mg initiation in type 2 diabetes mellitus patients during hot humid Indian summer","volume":"15","author":"Sanyal","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"2026011413231390600_CIT0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"key":"2026011413231390600_CIT0036","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"2026011413231390600_CIT0037","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"2026011413231390600_CIT0038","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ki.2013.336","article-title":"Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease","volume":"85","author":"Hung","year":"2014","journal-title":"Kidney Int"},{"key":"2026011413231390600_CIT0039","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1681\/ASN.0000000000000271","article-title":"Effects of empagliflozin on fluid overload, weight, and blood pressure in CKD","volume":"35","author":"Mayne","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026011413231390600_CIT0040","author":"KDIGO","year":"2021"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaf130\/63857737\/hpaf130.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/1\/122\/63857737\/hpaf130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/1\/122\/63857737\/hpaf130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:23:21Z","timestamp":1768415001000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/1\/122\/8214249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,7,25]]},"published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaf130","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,7,25]]}}}